Norris Medicines Ltd
NSE: BSE: 524414
₹14.49
(-3.40%)
Wed, 18 Mar 2026, 09:52 am
Market Cap0
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KNorris Medicines Analysis
dividend
- Unable to evaluate Norris Medicines's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Norris Medicines's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Norris Medicines's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Operating cash flow is negative therefore debt is not well covered.
- Norris Medicines has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
- Norris Medicines's long term commitments exceed its cash and other short term assets.
- Irrelevant to check if Norris Medicines's debt level has increased considering it has negative shareholder equity.
- Norris Medicines has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- High level of physical assets or inventory.
management
- The tenure for the Norris Medicines board of directors is about average.
- Vimal's remuneration is lower than average for companies of similar size in India.
- Vimal's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Norris Medicines management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- Norris Medicines is not covered by any analysts.
past
- Unable to compare Norris Medicines's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Norris Medicines does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Norris Medicines has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Norris Medicines improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Norris Medicines has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- Unable to compare Norris Medicines's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- BSE:524414 is up 6.1% along with the Pharmaceuticals industry (6.8%) over the past month.
- Norris Medicines has negative assets, we can't compare the value of its assets to the IN Pharmaceuticals industry average.
- Norris Medicines is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Norris Medicines is loss making, we can't compare the value of its earnings to the India market.
- 524414 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524414 underperformed the Market in India which returned -14.5% over the past year.
- BSE:524414 is up 6.1% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800